沙砾生物作为聚焦尖端生物科技的高新企业,专注肿瘤免疫治疗。其核心产品GT101注射液是中国首个获批注册临床的TIL药物,现已进入关键二期试验阶段。君实生物宣布拟以8000万元认购沙砾生物股份,增资后将合计持有5.1105%股权,此举有望加速TIL药物研发进程,为肿瘤治疗领域注入新动力。
Source Link沙砾生物作为聚焦尖端生物科技的高新企业,专注肿瘤免疫治疗。其核心产品GT101注射液是中国首个获批注册临床的TIL药物,现已进入关键二期试验阶段。君实生物宣布拟以8000万元认购沙砾生物股份,增资后将合计持有5.1105%股权,此举有望加速TIL药物研发进程,为肿瘤治疗领域注入新动力。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.